Researcher
Evelien Heylen
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Medical Biochemistry (Research group)
Member
From1 Oct 2006 → 30 Sep 2011
Projects
1 - 1 of 1
- Carboxypeptidase U: a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease.From1 Oct 2009 → 31 Mar 2011Funding: FWO fellowships
Publications
1 - 10 of 11
- Comparative study of commercially available procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) assays(2011)
Authors: Evelien Heylen, Johan Willemse, Dirk Hendriks
Pages: 1407 - 1409 - Carboxypeptidase U(2011)
Authors: Evelien Heylen
Number of pages: 256 - An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis(2011)
Authors: Evelien Heylen, Johan Willemse, Dirk Hendriks
Pages: 2427 - 2450 - Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis(2010)
Authors: Predrag Miljić, Evelien Heylen, Johan Willemse, Valentina Djordjević, Dragica Radojković, Milica Colović, Ivo Elezović, Dirk Hendriks
Pages: 74 - 78 - The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome(2010)
Authors: Raf Brouns, Evelien Heylen, Johan Willemse, R. Sheorajpanday, D. de Surgeloose, Robert Verkerk, Peter De Deyn, Dirk Hendriks
Pages: 75 - 80 - Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma(2010)
Authors: Evelien Heylen, Sebastiaan van Goethem, Johan Willemse, Thomas Olsson, Koen Augustyns, Dirk Hendriks
Pages: 152 - 154 - Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay(2010)
Authors: Evelien Heylen, Sebastiaan van Goethem, Koen Augustyns
Pages: 114 - 116 - Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?(2009)
Authors: Johan Willemse, Evelien Heylen, M.E. Nesheim, Dirk Hendriks
Pages: 1962 - 1971 - Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients(2009)
Authors: Raf Brouns, Evelien Heylen, Rishi Sheorajpanday, Johan Willemse, Jan Kunnen, Didier de Surgeloose, Dirk Hendriks, Peter De Deyn
Pages: 165 - 170 - Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia(2009)
Authors: Evelien Heylen, Predrag Miljic, Johan Willemse, Valentina Djordjevic, Dragica Radojkovic, Milica Colovic, Ivo Elezovic, Dirk Hendriks
Pages: 427 - 432